홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
NUVL
#912
Nuvalent, Inc. Class A Common Stock
101.950
0
-0.51%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-0.51%
월간 변동
-3.57%
6달 변화
+7.37%
년간 변동율
+7.37%
이전 종가
102.470
0
Open
101.950
0
Bid
Ask
Low
101.950
0
High
101.950
0
양
98
마켓
주식
헬스케어
NUVL
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
42.88 M
51.27 M
58.63 M
66.16 M
73.18 M
—
Valuation ratios
Enterprise value
2.69 B
4.69 B
14.29 B
4.27 T
5.49 T
18.24 T
Price to earnings ratio
-8.94
-17.56
-35.07
-19.92
-17.19
-64.88
Price to sales ratio
715.11
—
—
—
—
—
Price to cash flow ratio
-10.37
-22.15
-44.42
-28.09
26.57
-41.76
Price to book ratio
1.46
3.11
6.32
4.86
5.86
9.92
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.16
0.17
0.17
0.23
0.3
0.38
Return on equity %
0.16
0.18
0.18
0.24
0.34
0.43
Return on invested capital %
7 406.59
11.86 K
15 K
14.8 K
4 493.41
2 817.91
Gross margin %
100
—
—
—
—
—
Operating margin %
7 899.48
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
7 982.76
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
33.07
24.54
22.83
20.96
15.27
54.06
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.84
1.31
1.71
2.79
3.79
3.82
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
13.23
9.51
12.36
16.84
18.87
60.93
Net current asset value per share
13.34
9.62
12.48
17.05
19.16
61.79
Tangible book value per share
13.08
9.32
12.03
16.11
17.17
56.09
Working capital per share
12.94
9.23
11.93
16.24
17.9
57.2
Book value per share
13.08
9.32
12.03
16.11
17.17
56.09
뉴스
뉴밸런트, 4분기 손실 보고...폐암 치료제 FDA 결정 대기
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug
Drugmakers turn to AI to speed trials, regulatory submissions
Nuvalent, 52주 신고가 경신…112.89 USD 기록
Nuvalent Inc stock hits 52-week high at 112.89 USD
FDA, 뉴발렌트의 ROS1 양성 NSCLC 치료제 NDA 접수
FDA accepts Nuvalent’s NDA for ROS1-positive NSCLC treatment
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent CSO Pelish sells shares worth $501,752
Nuvalent (NUVL) chief development officer sells $721k in stock
What's Going On With Royalty Pharma Stock Wednesday? - Royalty Pharma (NASDAQ:RPRX)
3 Biotech Stocks With Major 2026 Catalysts